同型半胱氨酸抑制主动脉内皮细胞生长的研究  

Inhibitory effects of homocysteine on growth of cultured endothelial cells

作　　者：陈小莉[1] 杨庆 蔡东联[1] 卫立辛 

机构地区：[1]第二军医大学长海医院营养科,全军临床营养中心,上海200433 [2]东方肝胆外科研究所肿瘤免疫与基因治疗中心

出　　处：《第二军医大学学报》2002年第2期196-199,共4页Academic Journal of Second Military Medical University

基　　金：国家重点基础研究发展规划基金资助项目(G2 0 0 0 0 570 0 1 )

摘　　要：目的 :探讨同型半胱氨酸 (HCY)对内皮细胞 (EC)生长和功能的影响 ,了解 HCY引起动脉粥样硬化的过程及其可能机制。方法 :体外培养新生牛主动脉 EC,随机分为 6组 ,即正常对照组 ,及 HCY 0 .1、0 .5、1.0、5 .0和 10 .0 mmol/ L组 ;培养2 4 h后 ,显微镜下观察细胞形态同时采用细胞毒试验 ,流式细胞仪检测细胞生长情况 ,检测培养液中的一氧化氮 (NO)、内皮素 (ET)、前列腺素 (PGI2 )、血栓素 (TXA2 )、氧化型低密度脂蛋白 (ox- L DL)。 结果 :HCY各组的内皮细胞与对照组相比 ,细胞形态不规则 ,立体感差 ,细胞内颗粒多 ;细胞毒试验发现 HCY对 EC的生长与增殖有明显抑制作用 ;流式细胞仪检测可见HCY抑制 EC由 G1 期进入合成的 S期 ;功能检测可见 HCY组 EC释放的血管舒张因子 NO、PGI2 浓度降低 ;血管收缩因子ET、TXA2 升高 ;对内皮细胞有一定损害作用的 ox- L DL含量显著增加。结论 :HCY抑制 EC生长且损伤内皮细胞功能 。Objective:To investigate the effects of hom ocysteine on the development of atherosclerosis (AS) and its possible m echanism . Methods:Bovine aortic endothelial cells were cultured and treated with hom ocysteine for 2 4 h,the cultured cells were examined by MTT colorim etric assay,flow cytom etric method(FCM) . Meanwhile,the contents of nitric oxide (NO ) ,endothelin(ET) ,prostacyclin I2 (PGI2 ) ,thromboxane A2 (TXA2 ) in the media were determined. Results:(1) Homocysteine had an inhibitory effect on the proliferation and morphology of aortic endothelial cells;(2 ) Hom ocysteine prevented aortic endothelial cell from G1 - phase into S- phase in DNA synthesis;(3) Vascular relaxing factor NO and PGI2 contents in culture m edia in hom ocysteine group were significantly lower than that of control group;(4) Vasoconstrictors- ET and TXA2 were m arkedly higher than that of control group;(5 ) Oxidized low density lipoprotein (ox- L DL ) which had a harm ful effect on endothelial was higher than that of control group. Conclusion:Hom ocysteine has a definite harm ful effect on the aortic endothelial cells and this initial dam age may play a very im portant role in the process of AS form ation. [

关 键 词：同型半胱氨酸 血管内皮 动脉粥样硬化 主动脉内皮细胞 

分 类 号：R543.5[医药卫生—心血管疾病] R543.1[医药卫生—内科学]